Clinic-based magnetic pulses change targeted brain networks without surgery. Strongest human evidence supports treatment-resistant depression, with solid support for obsessive-compulsive symptoms with certain deep-stimulation systems. Short-term thinking-skill gains appear in mild cognitive impairment. Usual risks are scalp discomfort and headache; seizure is rare with screening. Not a simple wellness device or a substitute for sleep, training, and metabolic health. (Full Review)

Protocol

Course

5 days/week for 4–6 weeks

≈20–36 outpatient sessions; standard figure-8 left DLPFC depression course

Intensity

~120% resting motor threshold

High-frequency (e.g., 10 Hz) or iTBS; sessions minutes to ≈20–40 min

Accelerated option

Multiple iTBS sessions/day for ≈5 days

MRI-guided SAINT-style protocols in specialized centers

Time to effect

Depression

1–4 weeks

Improvement often emerges over a standard multi-session course

Accelerated protocols

Days

Some accelerated courses report faster mood shifts

Cognition

After multi-session programs

Durability of weeks reported in meta-analyses for MCI/AD protocols

Benefits

High: Reduction of depressive symptoms in treatment-resistant depression

Medium: Global cognition in mild cognitive impairment and Alzheimer disease; obsessive-compulsive symptom reduction; smoking cessation support; improved sleep quality in insomnia; migraine pain relief and prevention; post-stroke motor recovery

Low: Cognitive performance in neurologically healthy adults; anxiety symptom reduction

Speculative: Long-term cognitive resilience or dementia delay in at-risk adults without diagnosed impairment

Contraindications

Ferromagnetic or electronic implants in or near the head (e.g., certain aneurysm clips, cochlear implants not cleared for TMS environments)

Active or unstable epilepsy without specialist clearance

Acute alcohol withdrawal or uncontrolled substance withdrawal with seizure risk

Inability to provide consent or remain still for coil placement (relative)

Key Interactions

Proconvulsant medications (e.g., high-dose bupropion, clozapine, maprotiline)

Over-the-counter stimulants and decongestants (e.g., high-dose pseudoephedrine, oral caffeine products)

Alcohol binge or acute withdrawal

Stimulant intoxication or severe sleep deprivation

Other neuromodulation (ECT, implanted cortical stimulators, concurrent tDCS courses)

Supplements that are strongly stimulating or proconvulsant in excess (e.g., very high-dose caffeine, ephedra-like agents)

Sedating agents causing profound drowsiness

Risk & Side Effects

High: Transient headache and scalp discomfort; need for hearing protection / acoustic risk

Medium: Seizure; syncope or vasovagal responses

Low: Treatment-emergent mania or hypomania; transient mental fatigue or concentration difficulty after sessions

Speculative: Unknown long-term structural or network effects of repeated enhancement courses in healthy brains

Monitoring

Marker	Target	Why
TSH	≈0.5–2.5 mIU/L	Thyroid dysfunction mimics depression/cognitive impairment
Fasting glucose / HbA1c	Glucose ≈70–90 mg/dL; HbA1c ≈4.8–5.3%	Metabolic health affects cognition and mood
25-OH vitamin D	≈40–60 ng/mL	Deficiency linked to mood and cognition
CBC / comprehensive metabolic panel	Within lab reference	Baseline safety before intensive courses
Depression scale (e.g., PHQ-9, MADRS)	Track ≥50% drop (response) or below remission cutoffs	Primary efficacy metric for mood courses
Cognitive battery (e.g., MoCA, targeted memory/executive tests)	Improvement vs personal baseline	Primary metric for MCI/cognitive protocols

Cadence: Symptom scales at baseline, weekly mid-course, end of course, and about 4–12 weeks; cognitive batteries at end-course and after several weeks

Qualitative Assessment

Daily sleep quality and continuity
Work or creative cognitive stamina
Mood stability and anhedonia
Session tolerability (pain, headache, anxiety)

Transcranial Magnetic Stimulation for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment